Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670593 | 1.00 | MMP13 (0.42) | MMP13MAPTGPR119STSALDH1A1 | |
| SCHEMBL5670588 | 0.77 | OPRL1 (0.44) | MMP13MAPTGPR119STSALDH1A1 | |
| SCHEMBL5670590 | 0.77 | OPRL1 (0.44) | MMP13MAPTGPR119STSALDH1A1 | |
| SCHEMBL21523707 | 0.74 | SMN1; SMN2 (0.52) | MAPTGPR119STSSMN1; SMN2 | |
| SCHEMBL24629830 | 0.72 | STS (0.50) | MAPTGPR119STSALDH1A1SMN1; SMN2 | |
| SCHEMBL29535159 | 0.72 | STS (0.50) | MAPTGPR119STSALDH1A1SMN1; SMN2 | |
| SCHEMBL20438978 | 0.72 | SMN1; SMN2 (0.59) | MAPTGPR119ALDH1A1LMNACYP3A4 | |
| SCHEMBL22059962 | 0.72 | KDM4E (0.46) | STSOPRL1GRM5SMN1; SMN2 | |
| SCHEMBL4786221 | 0.72 | CNR1 (0.56) | MAPTSTSGRM5SMN1; SMN2 | |
| SCHEMBL30700671 | 0.72 | KDM4E (0.46) | STSOPRL1GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | MMP13 29/4885MAPT 4819/4885GPR119 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.